CAR T-Cell Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032

Description

Persistence Market Research has recently released a comprehensive report on the worldwide market for CAR T-cell therapy. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global CAR T-cell therapy market from 2025 to 2032.

Key Insights:

CAR T-Cell Therapy Market Size (2025E): US$ 5.8 Billion
Projected Market Value (2032F): US$ 24 Billion
Global Market Growth Rate (CAGR 2025 to 2032): 25%

CAR T-Cell Therapy Market - Report Scope:

CAR T-cell therapy is an advanced form of immunotherapy that involves genetically modifying a patient's T-cells to recognize and destroy cancer cells. This revolutionary treatment has demonstrated significant success in treating hematological malignancies such as lymphoma, leukemia, and multiple myeloma. The CAR T-cell therapy market encompasses approved therapies, pipeline products, manufacturing technologies, and clinical applications targeting a wide range of cancer indications. Market growth is driven by increasing cancer prevalence, rising adoption of personalized medicine, and continuous advancements in gene-editing and cell-engineering technologies.

Market Growth Drivers:

The global CAR T-cell therapy market is propelled by several key factors, including the growing incidence of hematologic cancers and the increasing demand for highly effective targeted therapies. The proven clinical efficacy of CAR T-cell therapies in relapsed and refractory cancer patients has significantly accelerated adoption across healthcare systems. Continuous innovation in cell engineering, manufacturing processes, and target antigen development is expanding therapeutic applications and improving treatment outcomes. Furthermore, growing investments in oncology research, favorable regulatory support for breakthrough therapies, and increasing awareness among healthcare providers are contributing to market expansion. The development of next-generation allogeneic CAR T-cell therapies is also expected to enhance accessibility and reduce treatment costs.

Market Restraints:

Despite strong growth prospects, the CAR T-cell therapy market faces challenges related to high treatment costs, complex manufacturing processes, and limited accessibility in certain regions. The individualized nature of autologous CAR T-cell therapies requires sophisticated production infrastructure and extended manufacturing timelines. Additionally, safety concerns such as cytokine release syndrome (CRS) and neurotoxicity necessitate specialized clinical monitoring and management. Reimbursement challenges and stringent regulatory requirements for cell-based therapies further create barriers to widespread adoption, particularly in developing healthcare markets.

Market Opportunities:

The CAR T-cell therapy market presents substantial opportunities driven by advancements in gene-editing technologies, expanding clinical indications, and ongoing research into solid tumor applications. The emergence of off-the-shelf allogeneic CAR T-cell therapies has the potential to revolutionize treatment accessibility and scalability. Increasing collaborations between biotechnology companies, academic institutions, and healthcare organizations are accelerating innovation and commercialization efforts. Moreover, the exploration of novel target antigens, combination therapies, and enhanced manufacturing platforms offers promising avenues for market growth. Expansion into emerging markets and the integration of artificial intelligence in therapy development and patient monitoring are expected to create additional opportunities for industry participants.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the CAR T-cell therapy market globally?
Which drug types and target antigens are contributing most significantly to market expansion?
How are technological advancements reshaping the competitive landscape of the CAR T-cell therapy market?
Who are the key players contributing to the CAR T-cell therapy market, and what strategies are they employing to maintain market leadership?
What are the emerging trends and future prospects in the global CAR T-cell therapy market?

Competitive Intelligence and Business Strategy:

Leading players in the global CAR T-cell therapy market, including Gilead Sciences, Inc., Novartis AG, and Bristol-Myers Squibb Company, focus on expanding product portfolios, advancing clinical pipelines, and strengthening manufacturing capabilities to gain a competitive advantage. These companies invest heavily in research and development to improve treatment efficacy, safety profiles, and production scalability. Strategic collaborations, licensing agreements, acquisitions, and partnerships with academic institutions are common approaches to accelerate innovation and market penetration. Additionally, efforts to develop next-generation CAR T-cell therapies targeting solid tumors and novel antigens are expected to shape the future competitive landscape of the industry.

Key Companies Profiled:

Gilead Sciences, Inc.
Novartis AG
Bristol-Myers Squibb Company
Legend Biotech Corporation
Cellectis S.A.
Autolus Therapeutics Plc
Adaptimmune Therapeutics plc
Mustang Bio, Inc.
Bellicum Pharmaceuticals, Inc.
MaxCyte, Inc.
Tessa Therapeutics
Caribou Biosciences, Inc.
Takeda Pharmaceutical Company Limited
Sorrento Therapeutics, Inc.
Poseida Therapeutics, Inc.

CAR T-Cell Therapy Market Research Segmentation:

By Drug Type:

Yescarta
Kymriah
Breyanzi
Abecma
Carvykti
Tecartus
Others

By Target Antigen:

CD19
BCMA
CD22
CD33
HER2
HER1
Others

By Disease Indication:

Lymphoma
Leukemia
Multiple Myeloma
Acute Myeloid Leukemia (AML)
Others

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP28264

1. Executive Summary

1.1. Global CAR T-Cell Therapy Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Target Antigen Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
2.3. Macro-economic Factors
- 2.3.1. Global Sectoral Outlook
- 2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Tool Adoption Analysis
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.4. PESTLE Analysis
3.5. Porter's Five Force Analysis

4. Price Analysis, 2024A

4.1. Key Highlights
4.2. Key Factors Impacting Deployment Costs
4.3. Pricing Analysis, By Disease Indication

5. Global CAR T-Cell Therapy Market Outlook

5.1. Key Highlights
- 5.1.1. Market Volume (Units) Projections
- 5.1.2. Market Size (US$ Bn) and Y-o-Y Growth
- 5.1.3. Absolute $ Opportunity
5.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
- 5.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 5.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
5.3. Global CAR T-Cell Therapy Market Outlook: Drug Type
- 5.3.1. Introduction / Key Findings
- 5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Drug Type, 2019 - 2024
- 5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
  - 5.3.3.1. Yescarta
  - 5.3.3.2. Kymriah
  - 5.3.3.3. Breyanzi
  - 5.3.3.4. Abecma
  - 5.3.3.5. Carvykti
  - 5.3.3.6. Tecartus
  - 5.3.3.7. Others
- 5.3.4. Market Attractiveness Analysis: Drug Type
5.4. Global CAR T-Cell Therapy Market Outlook: Target Antigen
- 5.4.1. Introduction / Key Findings
- 5.4.2. Historical Market Size (US$ Bn) Analysis, By Target Antigen, 2019 - 2024
- 5.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
  - 5.4.3.1. CD19
  - 5.4.3.2. BCMA
  - 5.4.3.3. CD22
  - 5.4.3.4. CD33
  - 5.4.3.5. HER2
  - 5.4.3.6. HER1
  - 5.4.3.7. Others
- 5.4.4. Market Attractiveness Analysis: Target Antigen
5.5. Global CAR T-Cell Therapy Market Outlook: Disease Indication
- 5.5.1. Introduction / Key Findings
- 5.5.2. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019 - 2024
- 5.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
  - 5.5.3.1. Lymphoma
  - 5.5.3.2. Leukemia
  - 5.5.3.3. Multiple Myeloma
  - 5.5.3.4. Acute Myeloid Leukemia (AML)
  - 5.5.3.5. Others
- 5.5.4. Market Attractiveness Analysis: Disease Indication

6. Global CAR T-Cell Therapy Market Outlook: Region

6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019 - 2024
6.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025 - 2032
- 6.3.1. North America
- 6.3.2. Europe
- 6.3.3. East Asia
- 6.3.4. South Asia and Oceania
- 6.3.5. Latin America
- 6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region

7. North America CAR T-Cell Therapy Market Outlook

7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
- 7.2.1. By Country
- 7.2.2. By Drug Type
- 7.2.3. By Target Antigen
- 7.2.4. By Disease Indication
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
- 7.3.1. U.S.
- 7.3.2. Canada
7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
- 7.4.1. Yescarta
- 7.4.2. Kymriah
- 7.4.3. Breyanzi
- 7.4.4. Abecma
- 7.4.5. Carvykti
- 7.4.6. Tecartus
- 7.4.7. Others
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
- 7.5.1. CD19
- 7.5.2. BCMA
- 7.5.3. CD22
- 7.5.4. CD33
- 7.5.5. HER2
- 7.5.6. HER1
- 7.5.7. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 7.6.1. Lymphoma
- 7.6.2. Leukemia
- 7.6.3. Multiple Myeloma
- 7.6.4. Acute Myeloid Leukemia (AML)
- 7.6.5. Others
7.7. Market Attractiveness Analysis

8. Europe CAR T-Cell Therapy Market Outlook

8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
- 8.2.1. By Country
- 8.2.2. By Drug Type
- 8.2.3. By Target Antigen
- 8.2.4. Disease Indication
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
- 8.3.1. Germany
- 8.3.2. France
- 8.3.3. U.K.
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Russia
- 8.3.7. Turkiye
- 8.3.8. Rest of Europe
8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
- 8.4.1. Yescarta
- 8.4.2. Kymriah
- 8.4.3. Breyanzi
- 8.4.4. Abecma
- 8.4.5. Carvykti
- 8.4.6. Tecartus
- 8.4.7. Others
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
- 8.5.1. CD19
- 8.5.2. BCMA
- 8.5.3. CD22
- 8.5.4. CD33
- 8.5.5. HER2
- 8.5.6. HER1
- 8.5.7. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 8.6.1. Lymphoma
- 8.6.2. Leukemia
- 8.6.3. Multiple Myeloma
- 8.6.4. Acute Myeloid Leukemia (AML)
- 8.6.5. Others
8.7. Market Attractiveness Analysis

9. East Asia CAR T-Cell Therapy Market Outlook

9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
- 9.2.1. By Country
- 9.2.2. By Drug Type
- 9.2.3. By Target Antigen
- 9.2.4. By Disease Indication
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
- 9.4.1. Yescarta
- 9.4.2. Kymriah
- 9.4.3. Breyanzi
- 9.4.4. Abecma
- 9.4.5. Carvykti
- 9.4.6. Tecartus
- 9.4.7. Others
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
- 9.5.1. CD19
- 9.5.2. BCMA
- 9.5.3. CD22
- 9.5.4. CD33
- 9.5.5. HER2
- 9.5.6. HER1
- 9.5.7. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 9.6.1. Lymphoma
- 9.6.2. Leukemia
- 9.6.3. Multiple Myeloma
- 9.6.4. Acute Myeloid Leukemia (AML)
- 9.6.5. Others
9.7. Market Attractiveness Analysis

10. South Asia & Oceania CAR T-Cell Therapy Market Outlook

10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
- 10.2.1. By Country
- 10.2.2. By Drug Type
- 10.2.3. By Target Antigen
- 10.2.4. By Disease Indication
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
- 10.3.1. India
- 10.3.2. Southeast Asia
- 10.3.3. ANZ
- 10.3.4. Rest of South Asia & Oceania
10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
- 10.4.1. Yescarta
- 10.4.2. Kymriah
- 10.4.3. Breyanzi
- 10.4.4. Abecma
- 10.4.5. Carvykti
- 10.4.6. Tecartus
- 10.4.7. Others
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
- 10.5.1. CD19
- 10.5.2. BCMA
- 10.5.3. CD22
- 10.5.4. CD33
- 10.5.5. HER2
- 10.5.6. HER1
- 10.5.7. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 10.6.1. Lymphoma
- 10.6.2. Leukemia
- 10.6.3. Multiple Myeloma
- 10.6.4. Acute Myeloid Leukemia (AML)
- 10.6.5. Others
10.7. Market Attractiveness Analysis

11. Latin America CAR T-Cell Therapy Market Outlook

11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
- 11.2.1. By Country
- 11.2.2. By Drug Type
- 11.2.3. By Target Antigen
- 11.2.4. By Disease Indication
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
- 11.3.1. Brazil
- 11.3.2. Mexico
- 11.3.3. Rest of Latin America
11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
- 11.4.1. Yescarta
- 11.4.2. Kymriah
- 11.4.3. Breyanzi
- 11.4.4. Abecma
- 11.4.5. Carvykti
- 11.4.6. Tecartus
- 11.4.7. Others
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
- 11.5.1. CD19
- 11.5.2. BCMA
- 11.5.3. CD22
- 11.5.4. CD33
- 11.5.5. HER2
- 11.5.6. HER1
- 11.5.7. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 11.6.1. Lymphoma
- 11.6.2. Leukemia
- 11.6.3. Multiple Myeloma
- 11.6.4. Acute Myeloid Leukemia (AML)
- 11.6.5. Others
11.7. Market Attractiveness Analysis

12. Middle East & Africa CAR T-Cell Therapy Market Outlook

12.1. Key Highlights
12.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
- 12.2.1. By Country
- 12.2.2. By Drug Type
- 12.2.3. By Target Antigen
- 12.2.4. By Disease Indication
12.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
- 12.3.1. GCC Countries
- 12.3.2. Egypt
- 12.3.3. South Africa
- 12.3.4. Northern Africa
- 12.3.5. Rest of Middle East & Africa
12.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
- 12.4.1. Yescarta
- 12.4.2. Kymriah
- 12.4.3. Breyanzi
- 12.4.4. Abecma
- 12.4.5. Carvykti
- 12.4.6. Tecartus
- 12.4.7. Others
12.5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
- 12.5.1. CD19
- 12.5.2. BCMA
- 12.5.3. CD22
- 12.5.4. CD33
- 12.5.5. HER2
- 12.5.6. HER1
- 12.5.7. Others
12.6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
- 12.6.1. Lymphoma
- 12.6.2. Leukemia
- 12.6.3. Multiple Myeloma
- 12.6.4. Acute Myeloid Leukemia (AML)
- 12.6.5. Others
12.7. Market Attractiveness Analysis

13. Competition Landscape

13.1. Market Share Analysis, 2024
13.2. Market Structure
- 13.2.1. Competition Intensity Mapping By Market
- 13.2.2. Competition Dashboard
13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 13.3.1. Gilead Sciences, Inc.
  - 13.3.1.1. Overview
  - 13.3.1.2. Segments and Deployments
  - 13.3.1.3. Key Financials
  - 13.3.1.4. Market Developments
  - 13.3.1.5. Market Strategy
- 13.3.2. Novartis AG
- 13.3.3. Bristol-Myers Squibb Company
- 13.3.4. Legend Biotech Corporation
- 13.3.5. Cellectis S.A.
- 13.3.6. Autolus Therapeutics Plc
- 13.3.7. Adaptimmune Therapeutics plc
- 13.3.8. Mustang Bio, Inc.
- 13.3.9. Bellicum Pharmaceuticals, Inc.
- 13.3.10. MaxCyte, Inc.
- 13.3.11. Tessa Therapeutics
- 13.3.12. Caribou Biosciences, Inc.
- 13.3.13. Takeda Pharmaceutical Company Limited
- 13.3.14. Sorrento Therapeutics, Inc.
- 13.3.15. Poseida Therapeutics, Inc.

14. Appendix

14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations